Trial Profile
A Phase Ib/II Study of BBI608 in Combination With Pembrolizumab in Patients With Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Napabucasin (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Cancer metastases; Colon cancer; Colorectal cancer; Gastrointestinal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms SCOOP
- 23 Apr 2021 Status changed from active, no longer recruiting to discontinued.
- 12 Jul 2020 Primary endpoint has not been met. (irORR)
- 12 Jul 2020 Results published in the Clinical Cancer Research